WAVEMAN · COMPANY

OKYO · Okyo Pharma Ltd

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

OKYO

Name: OKYO Pharma Ltd (OKYO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

OKYO Pharma Ltd

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001849296

CLUSTER · 6 INSIDERSC-SUITE BUYING · 4☆ WATCH

INSIDER NET · 180D

$136.0K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$136.0K over 180 days

+$136.0K over 90 days · +$67.6K of it by a 10%+ holder

more than 77% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

10 funds added or opened last quarter

below 82% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

0.3% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 83% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

6 insiders independently bought a net $136.0K — no planned sales are queued against it.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -32.3%

-32.3%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

6 insiders reported buying shares.

The record shows a net $136.0K bought by insiders over 180 days, 10 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, OKYO Pharma Ltd insiders bought a net $136.0K of stock across 13 Form 4 purchases and sales, with 6 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Patil Rajkumar V.

Chief Scientific Officer

BUY

2026-07-27

3,363.0

$5.0K

Dempsey Robert John

CHIEF EXECUTIVE OFFICER

BUY

2026-07-22

15,000.0

$23.1K

BRANCACCIO JOHN P

Director

BUY

2026-07-21

5,000.0

$7.4K

JACOB GARY S

CHIEF DEVELOPMENT OFFICER

BUY

2026-07-21

3,500.0

$4.9K

CERRONE GABRIELE M

Director

BUY

2026-07-21

22,500.0

$32.6K

13 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 8 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Woodline Partners LP

3,652,768.0 sh

$5.5M

Stonepine Capital Management, LLC

1,725,992.0 sh

$2.6M

Maven Securities LTD

809,317.0 sh

$1.2M

Balyasny Asset Management L.P.

580,596.0 sh

$870.9K

Opaleye Management Inc.

375,204.0 sh

$562.8K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Clinical pipeline

ClinicalTrials.gov · 2 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-03	2024-03	2023-03	2022-03
NET INCOME	$-4.7M	$-16.8M	$-13.3M	$-5.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE